MX2020007323A - Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica. - Google Patents

Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica.

Info

Publication number
MX2020007323A
MX2020007323A MX2020007323A MX2020007323A MX2020007323A MX 2020007323 A MX2020007323 A MX 2020007323A MX 2020007323 A MX2020007323 A MX 2020007323A MX 2020007323 A MX2020007323 A MX 2020007323A MX 2020007323 A MX2020007323 A MX 2020007323A
Authority
MX
Mexico
Prior art keywords
core
elastomer
active agent
therapeutically active
filler
Prior art date
Application number
MX2020007323A
Other languages
English (en)
Inventor
Antti Keinänen
Manja Ahola
Henriikka Korolainen
Risto Hakala
Piia Hara
Jyrki Pihlaja
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of MX2020007323A publication Critical patent/MX2020007323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método para modificar la liberación de un agente terapéuticamente activo desde una matriz elastomérica, que comprende proporcionar un núcleo que comprende una matriz elastomérica y un agente terapéuticamente activo; sumergir el núcleo en una solución de recubrimiento de un elastómero, donde el elastómero comprende 20-35% en peso de un agente de relleno, calculado a partir de la cantidad total de agente de relleno y elastómero; curar el núcleo sumergido para proporcionar un núcleo recubierto. En este método, se proporciona la inmersión como un proceso continuo arrastrando el núcleo a través de la solución de recubrimiento, utilizando una velocidad de arrastre adecuada para proporcionar un espesor de recubrimiento de 5-100 µm; el agente de relleno se selecciona entre sílice, dióxido de titanio, sulfato de bario, carbono y las mezclas de los mismos; el elastómero comprendido en el núcleo y el elastómero comprendido en la solución de recubrimiento se seleccionan independientemente entre poli(dimetil)siloxanos, polietileno acetatos de vinilo (EVA), poliuretanos (PU), polihidroxietil-metacrilatos (PHEMA) y polimetil-metacrilatos (PMMA).
MX2020007323A 2017-09-27 2018-09-19 Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica. MX2020007323A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17193367 2017-09-27
EP18167014 2018-04-12
PCT/EP2018/075331 WO2019063382A1 (en) 2017-09-27 2018-09-19 METHOD FOR MODIFYING THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX

Publications (1)

Publication Number Publication Date
MX2020007323A true MX2020007323A (es) 2020-09-07

Family

ID=63592747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007323A MX2020007323A (es) 2017-09-27 2018-09-19 Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica.

Country Status (18)

Country Link
US (1) US11666552B2 (es)
EP (1) EP3687495A1 (es)
JP (1) JP7242648B2 (es)
KR (1) KR20200059224A (es)
CN (1) CN111148507B (es)
AU (1) AU2018340266A1 (es)
BR (1) BR112020005928A2 (es)
CA (1) CA3076768A1 (es)
CL (1) CL2020000778A1 (es)
CO (1) CO2020003454A2 (es)
IL (1) IL272878A (es)
JO (1) JOP20200067A1 (es)
MX (1) MX2020007323A (es)
PE (1) PE20211195A1 (es)
SG (1) SG11202001293SA (es)
TW (1) TW201919587A (es)
UY (1) UY37906A (es)
WO (1) WO2019063382A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1222897A (zh) * 1996-03-29 1999-07-14 盖里列奥公司 用于形成光学纤维的可剥离聚酰亚胺涂层之方法
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
AU2002210580A1 (en) * 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
US20020136573A1 (en) * 2001-01-25 2002-09-26 Xerox Corporation Infrared curing of fluoroelastomer coatings formed over silicone rubber in a fuser member
CA2531640C (en) * 2003-07-10 2013-06-18 Galen (Chemicals) Limited Intravaginal drug delivery devices
US7914841B2 (en) * 2006-02-09 2011-03-29 Cook Medical Technologies Llc Inline application of coatings
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
WO2011156648A1 (en) * 2010-06-09 2011-12-15 President And Fellows Of Harvard College Method for producing films
WO2012091680A1 (en) * 2010-12-30 2012-07-05 Nanyang Technological University A device for controlled release of a bioactive agent
KR20120135689A (ko) * 2011-06-07 2012-12-17 (주) 태웅메디칼 약물 방출 스텐트 코팅제의 제조방법 및 이에 의해 제조된 약물 방출 스텐트 코팅제
US20130236524A1 (en) * 2011-09-09 2013-09-12 Axxia Pharmaceuticals, Llc Silicone coated implant
US9434857B2 (en) * 2011-11-15 2016-09-06 Ethicon, Inc. Rapid cure silicone lubricious coatings
AR089765A1 (es) * 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
US20140037964A1 (en) * 2012-08-02 2014-02-06 Haipeng Zheng Optical Article Containing A Self-Healing Coating And Improved Initial Haze
US20160262923A1 (en) * 2013-10-18 2016-09-15 Bayer Oy Intrauterine delivery system
HUE046267T2 (hu) * 2015-01-21 2020-02-28 Bayer Oy Nem szteroid gyulladáscsökkentõ (NSAID) és progesztogén vegyületet tartalmazó gyógyszerbeviteli rendszer és elõállítási eljárások
ES3009909T3 (en) * 2015-05-13 2025-03-31 Bayer Oy Long acting drug delivery device in form of an implant or iud comprising levonorgestrel and ethinylestradiol
EP3393452B1 (en) * 2015-12-21 2021-08-04 Bayer Oy Method for manufacturing a drug delivery device
EP4233999A3 (en) * 2016-12-12 2023-11-22 The Regents of The University of California Implantable and non-invasive stimulators for gastrointestinal therapeutics

Also Published As

Publication number Publication date
US11666552B2 (en) 2023-06-06
RU2020113426A (ru) 2021-10-27
PE20211195A1 (es) 2021-07-01
IL272878A (en) 2020-04-30
CN111148507B (zh) 2023-09-26
TW201919587A (zh) 2019-06-01
CL2020000778A1 (es) 2020-09-25
CO2020003454A2 (es) 2020-04-13
CN111148507A (zh) 2020-05-12
KR20200059224A (ko) 2020-05-28
US20200276159A1 (en) 2020-09-03
RU2020113426A3 (es) 2022-02-22
WO2019063382A1 (en) 2019-04-04
AU2018340266A1 (en) 2020-03-05
SG11202001293SA (en) 2020-03-30
EP3687495A1 (en) 2020-08-05
JP7242648B2 (ja) 2023-03-20
JOP20200067A1 (ar) 2020-04-27
BR112020005928A2 (pt) 2020-10-06
UY37906A (es) 2019-02-28
JP2020535159A (ja) 2020-12-03
CA3076768A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2012003079A (es) Metodo para modificar quimicamente la region interna del tallo del cabello.
CR20170409A (es) Vaina expandible con secciones transversales elastoméricas
EP2095191A4 (en) INTERMEDIATE TRANSFER MEMBER AND MANUFACTURING METHOD THEREFOR
MX388898B (es) Proceso para producir un cuerpo curado fotocromico.
AR072366A1 (es) Metodo de preparacion de unidades aglutinantes revestidas
BR112014002196A2 (pt) método para a produção de um painel do piso, teto ou parede decorada
CL2012002804A1 (es) Esponja de un material compuesto porosa hemostatica que comprende una matriz de un biomaterial y un componente polimerico hidrofilico con grupos reactivos, dque estan asociados entre si de manera que el componente polimerico forma un recubrimiento sobre una superficie de dicha matriz, o esta impregnado o ambos.
BR112019001003A2 (pt) métodos para produzir placas de gesso com revestimento de polímero e placas de gesso produzidas através do método
EP3540022A4 (en) ANTI-FOULING COATING COMPOSITION, ANTI-FOULING COATING FILM, BASE MATERIAL WITH ANTI-FOULING COATING FILM AND METHOD FOR MANUFACTURING THE SAME, AND ANTI-FOULING METHOD
EP3459994A4 (en) FOAMED MOLDED BODIES, INSULATION RUBBER, COMPOSITE BODIES OF INSULATION RUBBER AND PANEL, AND METHOD FOR INCREASING THE SOUND TRANSFER LOSS
CL2008003886A1 (es) Composicion para estabilizar la espuma en una lechada de yeso en presencia de agua dura que comprende un alquil etoxi sulfato que incluye una parte hidrofila con grupos etoxi y una parte hidrofoba; metodo para formar una lechada de yeso; y panel de yeso.
BR112018008995A8 (pt) processo para fabricar um filme multicamadas, processo para fabricar um filme não respirável multicamadas, filme multicamadas, filme não respirável multicamadas, filme parcialmente respirável multicamadas e produto de higiene pessoal
AR087061A1 (es) Procedimiento para revestir una superficie con micelas
PE20120785A1 (es) Remojo y lavado concentrado
BR112015029938A2 (pt) sementes granuladas
CO6440553A2 (es) Mezcla aceleradora y método de uso
MX2014004924A (es) Sustrato impreso imprimado secuencialmente.
AR104710A1 (es) Método para producir un recubrimiento multicapa
BR112015017111A2 (pt) lente intraocular revestida e sua fabricação
MX2019001759A (es) Composicion de pretratamiento.
AR073492A1 (es) Metodo para dar forma al cabello
EP4151784A4 (en) FAST ONE-STEP GRADIENT METHOD FOR THE GENERATION OF NANOANTIBODIES
PH12016502536A1 (en) Composite preparation comprising 5-a-reductase inhibitor-containing film coating layer, and method for producing the composite preparation
BR112017011041A2 (pt) processo para a fabricação de composições de polipropileno reforçadas com fibra de vidro longa
CO2020003454A2 (es) Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica